Table 2.

Top 10 Results from Meta-analysis Across All Cohorts of Nonsynonymous, Stop, and Splice Variant Associations with Moderate to Severe COPD

Chr	SNP	Gene	Effect Allele	Effect Allele Overall Frequency	β Value	SE	Test for Heterogeneity		Direction*†	P Value
							I2 Statistic	Q Statistic
15	rs16969968	CHRNA5	A	0.36	0.27	0.035	68	13	+++++	1.7 × 10−14
16	rs181206	IL27	A	0.69	−0.16	0.036	1.2	4.0	−−−−−	4.7 × 10−6
11	rs8177374	TIRAP	T	0.16	0.19	0.045	31	5.8	+−−++	2.6 × 10−5
6	rs2070600	AGER	T	0.042	−0.33	0.079	28	5.6	−−++−	2.7 × 10−5
11	rs679620	MMP3	T	0.48	0.12	0.030	0	2.5	+++++	3.8 × 10−5
6	rs10499052	AKD1	A	0.27	0.15	0.036	0	1.8	+++++	4.0 × 10−5
6	rs59056467	MICAL1	T	0.32	0.13	0.033	0	1.5	+−+++	4.7 × 10−5
10	rs41290259	FAM208B	A	0.98	0.58	0.15	0	1.2	+??++	8.8 × 10−5
16	rs61746451	CRAMP1L	T	0.011	−0.57	0.14	0	2.4	−?+−−	8.9 × 10−5
14	rs28929474	SERPINA1	T	0.021	0.45	0.12	50	4.0	+?+?+	1.4 × 10−4

Definition of abbreviation: Chr = chromosome; COPD = chronic obstructive pulmonary disease; SNP = single-nucleotide polymorphism.

Only variants observed in at least three of the five analysis cohorts are reported.

^*The direction of effect is reported for each analysis cohort. The symbols from left to right represent (1) Boston Early-Onset COPD study and International COPD Genetics Network study, (2) Transcontinental COPD Genetics Study (TCGS) Korea cohort, (3) TCGS Poland cohort, (4) Genetic Epidemiology of COPD Study (COPDGene) African American cohort, and (5) COPDGene non-Hispanic white cohort.

^†The symbol for each cohort is “+” for effect allele association with increased COPD susceptibility, “−” for association with decreased COPD susceptibility, and “?” if the variant was not present at a sufficient allele count in the analysis cohort.